The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer. READ MORE

Conferences

Investigators assessed how response rate changed when patients were treated with different doses of brigatinib.

READ MORE

Investigators compared the safety and efficacy of docetaxel plus plinabulin with docetaxel alone in patients with NSCLC.

READ MORE

Using four key quality interventions in patients with non-small cell lung cancer who undergo surgery. 

READ MORE

How does stereotactic body radiation therapy affected rates of non-cancer-related deaths?

READ MORE

J Code Updates

News

The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer.

READ MORE

Long-term data from a recent trial suggest that continuation of treatment with first-generation EGFR TKIs beyond EGFR-positive NSCLC progression does not improve overall survival.

READ MORE

The American Society of Clinical Oncology has updated their guideline on systemic therapy for non-small cell lung cancer for the first time since 2015.

READ MORE

The NCCN has updated their treatment guidelines for NSCLC to include recommendations for BRAF mutation testing to guide therapy and a new first-line treatment option for non-squamous NSCLC.

READ MORE

Research in Review

A new prognostic model provides personalized and disease-specific predictive information for patients with non-small cell lung cancer (NSCLC) and may result in better survival outcomes.

READ MORE

A second-generation inhibitor delays anaplastic lymphoma kinase-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care.

READ MORE

Few patients treated with immunotherapy for metastatic non–small cell lung cancer at US community practices receive appropriate programmed death-ligand 1 expression testing.

READ MORE

Patients with non-small cell lung cancer and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival after thoracic surgery and systemic chemotherapy.

READ MORE